RE:The SP $value is ok...Bird, I totally agree with you on the science and the future. However, I totally disagree that a 0.115 US SP is "exactly where it should be". The current valuation is suitable for a start up that is still working in pietre dishes and test tubes. We have a Phase II trial that is 2/3s complete with "world class" results and we are currently in discussions with FDA regarding BTD, and probably AA in the next year. In no way does the current stock price reflect this. None of that is built into the current stock price.
TLT's market cap should be expotentially higher. There are hundreds and hundreds of small biotechs that have their futures already priced into their current stock price. That's why all stocks trade at multiples becasue markets are forward looking. Biotechs that are priced at 0.115 are there because maybe they received an FDA partial response letter, or they discontined their trial, or had a patient death, or their results showed no statistical significance...or any other number of reasons that would put a stock value so low. But that is obviously not the case with TLT.